LEAP regimen

DRUG2 trials

Sponsors

Rong Tao

Conditions

Extranodal NK/T-cell LymphomaNatural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Phase 2

Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma

CompletedNCT04004572

Rong TaoNatural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Start: 2019-07-01End: 2024-12-30Updated: 2026-08-03

Phase 3

BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL

RecruitingNCT07678229

Rong TaoExtranodal NK/T-cell Lymphoma

Start: 2026-08-11End: 2031-12-31Target: 150Updated: 2026-08-13

Related Papers

Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study.

2026-03-03

Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4).

2021-10-2781 citations